GLP-1 agonists: Difference between revisions
(internal link added) |
(added some points in the background section) |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
* Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists | * Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists | ||
* Stimulate insulin release from pancreatic islet cells | * Released by L-cells of the small intestinge in response to the presence of nutrients | ||
* Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas | |||
* Slows gastric emptying times | |||
* Increases satiety, which decreases drive for food intake | |||
==Types== | ==Types== | ||
{| class="wikitable" | {| class="wikitable" | ||
Revision as of 17:43, 5 September 2016
Background
- Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
- Released by L-cells of the small intestinge in response to the presence of nutrients
- Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
- Slows gastric emptying times
- Increases satiety, which decreases drive for food intake
Types
| Short Acting | Dose |
|---|---|
| Exenatide(Byetta) | 5-10 mcg SC bid |
| Liraglutide(Victoza) | 0.6-1.8 mg SC daily |
| Long Acting | |
| Exenatide(Bydureon) | 2 mg SC qwk |
| Albiglutide(Tanzeum) | 30-50 mg SC qwk |
| Dulaglutide(Trulicity) | 0.75-1.5 mg qwk |
Indication
- Diabetes Mellitus, Type 2
Adverse Reactions
- Nausea, vomiting, diarrhea
- Acute pancreatitis
- Exenatide should not be used in patients with creatinine clearance below 30mL/min
- Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B
See Also
References
1.Epocrates